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1. Introduction 
Considerable evidence has accumulated to sub- 
stantiate the role of circulating antigens and antigen- 
antibody complexes in the pathogenesis of many 
experimental and human diseases [1 ] . Soluble 
circulating antigens may combine with antibodies to 
form pathogenic immune complexes which deposit in 
tissues causing inflammation. Circulating soluble 
antigens may also block cell mediated cytotoxic activity 
directed to neoplastic cells [2] . 
In previous studies, we have demonstrated the fea- 
sibility of specifically removing circulating antibodies 
with extracorporeal immunoadsorbents [3,4]. The 
selective removal of antigens and immune complexes 
from the circulation would be another desirable 
goal [5] . 
We herein describe a novel immunoadsorbent in 
which antibodies or Clq have been immobilized in 
collodion membranes. When placed in an extra- 
corporeal circulation system, immobilized antibodies 
have shown a capacity to specifically withdraw 
circulating antigens and entrapped Clq has demonstrat- 
ed an ability to extract circulating antigen-antibody 
complexes. There was no evidence of release of the 
immobilized immune reactants and no demonstrable 
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toxicity to the host’s hematologic and biochemical 
status. 
In order to increase the efficiency of the immuno- 
adsorbent, a plasma-cell separator was employed for 
in vivo studies in which only circulating plasma was 
circulated over the immunoadsorbent surface. We 
herein demonstrate the feasibility of utilizing this 
device as an adjunct to removing immune reactants 
from the circulation with extracorporeal immuno- 
adsorbent. 
2. Materials and methods 
BSA antibodies were isolated from 50 ml of immune 
rabbit serum by the method of Ishizaka, et al. [6]. 
After concentration by ultra-filtration and dialysis 
against 0.1 M Tris buffer for 24 h at 4°C the final 
solution demonstrated an antigen binding capacity of 
33 I-18 BSA bound/ml of undiluted solution [7]. Clq 
was isolated from human serum by the method of 
Heusser et al. [8]. Approximately 10 mg of Clq was 
isolated from 1500 ml of human serum which demon- 
strated a single precipitin band against a monospecific 
rabbit antiserum to Clq (Behring Diagnostics, Somer- 
ville, N.J.). 
For preparation of BSA-anti-BSA complexes, 
quantitative precipitin curve was plotted utilizing 
r2’I-BSA and anti-BSA. The point in antigen excess at 
which no spontaneous precipitation occurred was 
determined. For the anti-BSA used, this occurred at 
1000 pg of BSA/ml serum. The isolation of soluble 
r2’I-BSA-anti-BSA complexes was completed accord- 
ing to our previously described procedure [lo]. 
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2.1. Preparation of collodion membranes containing 
an ti-BSA antibodies or Clq 
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The membrane casting equipment consisted of a 
bell jar mandrel 16 cm in length and 16 cm in diameter, 
which was rotated horizontally at 200 rev/min a 
mechanical pump. A solution containing 50 ml of 
collodion (Mallinckrodt, Inc., St. Louis, MO.), 10 ml of 
absolute alcohol and 30 ml of anhydrous ether 
(Mallinckrodt, Inc., St. Louis, MO.) was prepared. This 
solution was poured horizontally from a narrow mouth 
beaker over the rotating mandrel. A second solution 
consisting of 1 ml of collodion, 1.3 ml of absolute 
alcohol, 20 ml of ether was prepared in a 50 ml syringe 
with a stop cock attached to the outlet. A mototool 
(Dremel Co., Racine Wisconsin, Model 270) with a 
wire mixer at the end facilitated stirring of the solu- 
tion. While the collodion-ether-alcohol solution was 
being stirred, 1 ml of anti-BSA or Clq plus I31 I anti- 
BSA [9] or r3rI-Clq [9] in 0.1 M Tris buffer was 
added drop-wise. This second solution was then 
poured slowly and evenly through the open stop cock 
with constant stirring over the semi-dry collodion base 
layer which was rotating at 200 ml/min on the mandrel. 
The entire membrane was then rotated for an additional 
15 min until it was semi-dry. The membrane was then 
detached, washed in 0.1 M Tris buffer for 10 min 
at 27”C, wrapped in spiral fashion over an inert backing 
material and then placed in glass chambers 8 cm in 
length and 2.5 cm in diameter with 40 mesh stainless 
steel screens at the ends. The chambers were then 
filled with 0.1 M Tris buffer and held at 4°C for 1 h 
after which phosphate buffered saline, pH 7.4, was 
substituted and incubated for an additional 18 h at 
4°C. Schematic representation of this preparation is 
shown in fig.1. 
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Fig.1. Schematic representation of the preparation of immuno- 
reactive collodion membranes is depicted. 
2.2. In vivo extracorporeal system 
Dogs were anesthetized with sodium pentabarbitol (Clay-Adams, Parsippany, N.J.). Formed elements of 
and the femoral artery and vein cannulated with wide the blood, separated in the celltrifuge, were pumped 
bore polyethylene tubing. Sodium heparin 3 mg/kg at 40 nil/min to a site where they rejoined the plasma 
was injected intravenously into the femoral artery and coming from the glass chambers. The recombined whole 
the venous catheters were connected to a continuous blood passed through a drip chamber and bubble trap 
flow celltrifuge (American Instruments Co., Silver and then to the femoral vein. Heparinized blood was 
Springs, Maryland). Arterial blood entering the cell- circulated through the extracorporeal system for 
trifuge was separated into plasma and formed elements 20 min before intravenous injection of immune reac- 
by centrifugation. The plasma was them pumped at tants. Perfusion of the collodion membranes then pro- 
40 ml/min through glass chambers containing collodion ceeded for an additional 120 min. Schematic represen- 
membranes. Each chamber was siliconized before use tation of this in vivo system is shown in fig.2. 
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Fig.2. Schematic representation of the extracorporeal immunoadsorbent system is depicted. 
3. Results 
Anti-BSA antibodies 3.20 or 5.38 mg plus 13’1 
anti-BSA (1 Erg) as a marker was added to collodion 
and membranes prepared as described in Methods. 
After completion of the entrapment procedure, the 
anti-BSA membranes were placed in glass cylinder 
chambers and at the conclusion of in vitro or in vivo 
circulation studies, they were removed and counted 
in a gamma scintillation counter. The quantity of 
anti-BSA retained was calculated by determining the 
percentage of total 1311 anti-BSA added which was 
entrapped in the collodion membranes at the end of 
the experiments. The results shown in table 1 
Table 1 
Retention of anti-BSA in collodion membranes 
Experiment 
In vitro 
In vivo 
Quantity of 
anti-BSA 
added 
(mg) 
3.20 
5.38 
Quantity of 
lo11 anti-BSA Anti-BSA anti-BSA 
I31 I anti-BSA recovered in retained in retained in 
added membranes membranes membranes 
(cpm) (cpm) (%) (mg) 
52 128 21 538 40.8 1.30 
17 749 13 849 78.0 4.19 
Retention of Clq in collodion membranes 
Experiment 
In vitro 
In vivo 
Quantity of 
Clq added 
(mg) 
2.1 
4.5 
13’1 Clq 
added 
(cem) 
104 827 
107 266 
lJII Clq 
recovered 
in membranes 
kpm) 
100 606 
89 421 
Clq Quantity of 
retained Clq retained 
in membranes in membranes 
(%) (mg) 
95.9 2.01 
83.3 3.75 
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Fig.3. The kinetics of ?-BSA removal after in vitro circula- 
tion over anti-BSA or RGG collodion membranes is presented. 
demonstrate that 1.36 and 4.19 mg of anti-BSA were 
retained in collodion membranes. Clq membranes 
were similarly prepared and counted with 2.01 and 
3.75 mg entrapped in the membranes. 
One hundred ml of PBS, pH 7.4, containing 
1.2 X 10’ cpm of 12’I-BSA [9] (Miles Laboratory, 
Indianapolis, Indiana) was circulated by a dual channel 
roller pump at 70 ml/min through each of 2 chambers 
containing anti-BSA or rabbit gamma globulin (RGG) 
(Miles Laboratory, Indianapolis, Indiana) entrapped in 
collodion membranes. Aliquots of buffer were 
extracted from each circuit at various intervals and 
counted for 12’ I-BSA (flg.3). In addition, at the con- 
clusion of the experiments, control and experimental 
membranes were removed from chambers washed with 
400 ml 0.15 M NaCl and then counted in a gamma 
scintillation counter. Results shown in table 2 
demonstrate a nearly 600% increase in the retention 
of 12’I-BSA on the membrane in which anti-BSA was 
immobilized compared to the RGG membrane. No 
13iI anti-BSA which was incorporated in the membrane 
as a marker was recoverable from the final buffer 
sample (5 ml) above background cpm. 
In a similar in vitro circulation system 1.4 X 10’ cpm 
of 12’1-BSA-anti-BSA was circulated in each of 
2 circuits over Clq-collodion and control collodion 
membranes. The kinetics of immune complex removal 
is shown in iig.4. Clq and control membranes were 
counted at the conclusion of experiments and showed 
nearly 300% increase in binding of immune complexes 
to Clq collodion compared to the control membrane. 
No 1311-Clq [9] incorporated in the membrane as a 
marker was recoverable in the final buffer sample 
(5 ml) above background cpm. 
For in vivo studies, 12’I-BSA was infused into 
Table 2 
Uptake of lzsI BSA on anti-BSA collodion membranes 
Anti-BSA Normal gamma globulin 
Experiment collodion membranes colIodion membranes 
(cpm) (rg) (cpm) olg) 
In vitro 73 616 1.84 11484 0.28 
In vivo 177 783 4.44 74 459 1.86 
Uptake of lzsI BSA-anti-BSA on Clq collodion membranes 
Clq collodion Collodion 
membranes membranes 
(cpm) ocg) (cpm) &g) 
In vitro 81796 1.40 34 559 0.59 
In vivo 20 033 0.34 7 167 0.12 
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4. Discussion 
Control Circuit 
--~-_~~~~ 
These studies demonstrate that significant quantities 
of anti-BSA and Clq may be entrapped in collodion 
membranes. Once immobilized, anti-BSA and Clq 
appear to retain sufficient function to specifically 
withdraw circulating BSA and immune complexes 
respectively both in vitro and in vivo. In addition, 
there was no significant release of 13’ I anti-BSA 
from the membranes since (a) there was no change 
in I31 I anti-BSA or 13’ I-Clq on the membranes before 
and after the in vivo procedures, (b) no significant 
13’1 could be identified in a buffer sample taken at 
the conclusion of the in vitro circulation study, and (c) 
no significant uptake 13’ I was observed in the thyroid 
gland, urine or vital organs at the conclusion of in 
vivo experiments. Collodion has been employed to 
coat small charcoal particles which have been utilized 
for the treatment of a variety of intoxications as well 
as in the extra-corporeal therapy of chronic renal 
failure [ 11 ,121. The collodion membranes may 
possess many features of the optimal immunoadsorbent 
for in vivo use which include (a) large surface area 
capable of binding large quantities of functional 
protein, (b) large surface area with minimal extra- 
corporeal volume requirements, (c) firm adherence 
of the material entrapped in it without release into 
the host, and (d) minimal toxicity to the host’s 
hematologic and biochemical status. 
September 1976 
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Fig.4. The pattern of removal of 12%BSA-anti-BSA after 
circulation across Clq or control collodion membranes in 
vitro is shown. 
anesthetized dogs and plasma was then circulated over 
anti-BSA and RGG collodion membranes. Results 
shown in table 2 demonstrates that the membrane con- 
taining anti-BSA antibodies extracted nearly 250% 
more ‘251-BSA than the corresponding RGG membrane 
In a second in viva experiment, 1251-BSA-anti-BSA 
complexes were circulated over Clq and control cello- 
dion membranes. There was nearly 300% uptake of 
complexes on the Clq membrane compared to the 
control (table 2). 
To determine whether anti-BSA or Clq was released 
from the immunoadsorbent during the in vivo circulation 
studies, the vital organs, serum and urine of the dogs 
were counted for the presence of 1311 anti-BSA or 
1311-Clq at the conclusion of the experiments. No 
significant 13’ I anti-BSA was discovered in the organs, 
serum and urine of the dogs above background cpm. 
In addition, sample areas of the experimental collodion 
membranes were counted at the conclusion of the 
experiments and showed no significant change in 
1311 cpm from pre-perfusion values. Thus no significant 
“‘1 anti-BSA was released from the membrane during 
the experiments. 
Studies of hematocrit and leukocyte counts were 
performed on dogs before and after extracorporeal 
circulation revealed no significant alterations and there 
were no changes in serum sodium, potassium, calcium, 
magnesium and creatinine. 
The continuous flow celltrifuge employed in these 
studies has been utilized in the past for leukocyte and 
platelet collection from blood donors [ 13,141. In the 
foregoing studies, we demonstrate the feasibility of 
using the celltrifuge to assist in withdrawal of circulat- 
ing immune reactants. The celhrifuge might maximize 
the efficiency of specific antibody clearance by (a) 
increasing the contact of circulating antibodies with 
the immunoadsorbent surface and (b) preventing 
cellular deposition that might coat combining sites 
immobilized in the immunoadsorbent. Celltrifuge 
might also be of value in circumstances where it 
would be desirable to reutilize the imrnunoadsorbent 
by minimizing cellular deposits and therefore 
facilitating cleansing of the column. 
The foregoing study represents a step in the devel- 
opment of technology toward the use of an effective 
immunoadsorbent to remove circulating pathogenic 
antigens and immune complexes. Indeed, many 
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antigens have been identified in disease processes 
which appear to play an important pathogenic role, 
namely, native and single stranded DNA in systemic 
lupus erythematosus, which, when combined with 
specific antibody form immune complexes which 
deposit in tissues causing tissue inflammation and 
destruction [ 151. In addition, circulating tumor 
antigens have been shown to block vital lymphocyte 
functions in vitro [ 16,171. indeed, numerous diseases 
have been shown to be mediated by antigen-antibody 
complexes [l] and sensitive assays to monitor their 
quantity in serum have been described. Removal of 
pathogenic immune complexes from the circulation 
would be a desireable therapeutic objective and 
immobilized Clq might serve as an instrument for 
this purpose. 
In the system herein described, one collodion mem- 
brane consisted of approximately 1000 cm* with a 
fluid volume requirement per chamber of only 20 ml. 
Recently, we have shown that these collodion mem- 
branes may incorporate up to 50 mg of protein [ 181. 
Therefore, this membrane system may be markedly 
scaled up to incorporate larger quantities of antibody 
or Clq. Present studies are examining this possibility 
of removing larger quantities of antigen and immune 
complexes from the circulation of animals with 
naturally occurring autoimmune disease. 
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